Literature DB >> 22857748

Laparoscopic cryoablation of renal masses: single-center long-term experience.

Youssef S Tanagho1, Timur M Roytman, Sam B Bhayani, Eric H Kim, Brian M Benway, Michael W Gardner, R Sherburne Figenshau.   

Abstract

OBJECTIVE: To evaluate perioperative and long-term functional and oncological outcomes of laparoscopic cryoablation (LCA) performed at Washington University.
METHODS: A retrospective chart review was performed evaluating 62 consecutive patients who underwent LCA at our institution between 2000 and 2005.
RESULTS: Mean age-adjusted Charlson Comorbidity Index (CCI) was 6.1 (SD, 2.1; 95% confidence interval [CI], 5.6-6.6). Mean tumor size was 2.52 cm (SD, 0.99; CI, 2.3-2.8). Mean operative time was 162.0 minutes (SD, 66.6; CI, 142.0-182.1). Mean estimated blood loss was 84.9 mL (SD, 102; CI, 58.6-111.2). Mean hospital stay was 2.6 days (SD, 1.90; CI, 2.1-3.1). The perioperative complication rate was 9.7% (Clavien 1-2). Among patients with biopsy proven, localized renal cell carcinoma, the 6-year Kaplan-Meier estimated disease-free survival (DFS) was 80%; cancer-specific survival (CSS) was 100%; and overall survival (OS) was 76.2%. Mean follow-up in this subset was 76.0 months (SD, 39.3; CI, 62.7-89.4; n = 35), whereas mean time to cancer recurrence was 27.6 months (SD, 11.2; CI, 15.9-39.3; n = 6). Tumor size ≥2.6 cm was the only predictor of cancer recurrence in a multivariate Cox proportional hazards model (hazard ratio [HR] = 28.9; P = .046; n = 35). Mean preoperative estimated glomerular filtration rate (eGFR) was 68.3 (SD, 22.3; CI, 62.1-74.5), compared to 64.5 mL/min/1.73 m(2) (SD, 28.9; CI, 56.5-72.6) at last follow-up (P = .12; n = 52). Excluding patients requiring secondary ablative or extirpative treatments for recurrent renal cell carcinoma, preoperative eGFR <60 mL/min/1.73 m(2) (odds ratio [OR] = 88.3; P = .036) and age-adjusted CCI ≥6 (OR = 32.4; P = .046) were the only factors predicting renal disease progression on multiple logistic regression (n = 47).
CONCLUSION: We report what is by far the longest follow-up to date of postlaparoscopic cryoablation changes in eGFR and note excellent long-term renal functional outcomes. For those willing to accept the potential need for retreatment for recurrent disease, LCA offers excellent long-term CSS.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22857748     DOI: 10.1016/j.urology.2012.03.044

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

Review 2.  Laparoscopic renal cryoablation.

Authors:  Marc Schiffman; Amiel Moshfegh; Adam Talenfeld; Joseph J Del Pizzo
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 3.  Trends in Percutaneous Thermal Ablation Therapies in the Treatment of T1a Renal Cell Carcinomas Rather than Partial Nephrectomy/Radical Nephrectomy.

Authors:  Sepideh Shakeri; Steven S Raman
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

Review 4.  Mechanisms of cryoablation: clinical consequences on malignant tumors.

Authors:  J G Baust; A A Gage; T E Bjerklund Johansen; J M Baust
Journal:  Cryobiology       Date:  2013-11-13       Impact factor: 2.487

Review 5.  Ablative therapies for small renal tumours.

Authors:  Arturo Castro; Lawrence C Jenkins; Nelson Salas; Gideon Lorber; Raymond J Leveillee
Journal:  Nat Rev Urol       Date:  2013-04-23       Impact factor: 14.432

Review 6.  The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.

Authors:  Tobias Klatte; Nils Kroeger; Uwe Zimmermann; Martin Burchardt; Arie S Belldegrun; Allan J Pantuck
Journal:  World J Urol       Date:  2014-04-04       Impact factor: 4.226

7.  Percutaneous Cryoablation of Stage T1b Renal Cell Carcinoma: Safety, Technical Results, and Clinical Outcomes.

Authors:  Andrew J Gunn; Winston B Joe; Aliaksei Salei; Husameddin El Khudari; Khalid H Mahmoud; Eric Bready; Eric M Keasler; Patrick P Patten; Jennifer B Gordetsky; Soroush Rais-Bahrami; Ahmed K Abdel Aal
Journal:  Cardiovasc Intervent Radiol       Date:  2019-05-01       Impact factor: 2.740

Review 8.  Current status of cryotherapy for prostate and kidney cancer.

Authors:  Seok Cho; Seok Ho Kang
Journal:  Korean J Urol       Date:  2014-11-21

Review 9.  Indications for biopsy and the current status of focal therapy for renal tumours.

Authors:  Ricardo R N Leão; Patrick O Richard; Michael A S Jewett
Journal:  Transl Androl Urol       Date:  2015-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.